Patient-Derived Xenograft Models for Endometrial Cancer Research
Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patien...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1422-0067/19/8/2431 |
| _version_ | 1811217594717306880 |
|---|---|
| author | Cristian P. Moiola Carlos Lopez-Gil Silvia Cabrera Angel Garcia Tom Van Nyen Daniela Annibali Tina Fonnes August Vidal Alberto Villanueva Xavier Matias-Guiu Camilla Krakstad Frédéric Amant Antonio Gil-Moreno Eva Colas |
| author_facet | Cristian P. Moiola Carlos Lopez-Gil Silvia Cabrera Angel Garcia Tom Van Nyen Daniela Annibali Tina Fonnes August Vidal Alberto Villanueva Xavier Matias-Guiu Camilla Krakstad Frédéric Amant Antonio Gil-Moreno Eva Colas |
| author_sort | Cristian P. Moiola |
| collection | DOAJ |
| description | Endometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice. |
| first_indexed | 2024-04-12T06:57:29Z |
| format | Article |
| id | doaj.art-baa7c2a25b3c4857a60e4f69a30e029c |
| institution | Directory Open Access Journal |
| issn | 1422-0067 |
| language | English |
| last_indexed | 2024-04-12T06:57:29Z |
| publishDate | 2018-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-baa7c2a25b3c4857a60e4f69a30e029c2022-12-22T03:43:06ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-08-01198243110.3390/ijms19082431ijms19082431Patient-Derived Xenograft Models for Endometrial Cancer ResearchCristian P. Moiola0Carlos Lopez-Gil1Silvia Cabrera2Angel Garcia3Tom Van Nyen4Daniela Annibali5Tina Fonnes6August Vidal7Alberto Villanueva8Xavier Matias-Guiu9Camilla Krakstad10Frédéric Amant11Antonio Gil-Moreno12Eva Colas13Pathological Oncology Group, Biomedical Research Institute of Lleida (IRBLLEIDA), University Hospital Arnau de Vilanova, 25198 Lleida, SpainBiomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, SpainGynecological Oncology Department, Vall Hebron University Hospital, 08035 Barcelona, SpainPathology Department, Vall Hebron University Hospital, 08035 Barcelona, SpainDepartment of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, BelgiumDepartment of Oncology, Gynecological Oncology, KU Leuven, 3000 Leuven, BelgiumDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, NorwayDepartment of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, CIBERONC, L’Hospitalet del Llobregat, 08907 Barcelona, SpainXenopat S.L, Business Bioincubator, Bellvitge Health Science Campus, L’Hospitalet de Llobregat, 08907 Barcelona, SpainPathological Oncology Group and Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, 25198 Lleida, SpainDepartment of Obstetrics and Gynecology, Haukeland University Hospital, 5021 Bergen, NorwayCentre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI) and University Medical Centra (UMC), 1066 CX Amsterdam, The NetherlandsBiomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, SpainBiomedical Research Group in Gynecology, Vall Hebron Institute of Research, CIBERONC, 08035 Barcelona, SpainEndometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.http://www.mdpi.com/1422-0067/19/8/2431orthoxenograftuterine canceravatarmurine modelspersonalized medicinetargeted therapypreclinical studiestranslational research |
| spellingShingle | Cristian P. Moiola Carlos Lopez-Gil Silvia Cabrera Angel Garcia Tom Van Nyen Daniela Annibali Tina Fonnes August Vidal Alberto Villanueva Xavier Matias-Guiu Camilla Krakstad Frédéric Amant Antonio Gil-Moreno Eva Colas Patient-Derived Xenograft Models for Endometrial Cancer Research International Journal of Molecular Sciences orthoxenograft uterine cancer avatar murine models personalized medicine targeted therapy preclinical studies translational research |
| title | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| title_full | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| title_fullStr | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| title_full_unstemmed | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| title_short | Patient-Derived Xenograft Models for Endometrial Cancer Research |
| title_sort | patient derived xenograft models for endometrial cancer research |
| topic | orthoxenograft uterine cancer avatar murine models personalized medicine targeted therapy preclinical studies translational research |
| url | http://www.mdpi.com/1422-0067/19/8/2431 |
| work_keys_str_mv | AT cristianpmoiola patientderivedxenograftmodelsforendometrialcancerresearch AT carloslopezgil patientderivedxenograftmodelsforendometrialcancerresearch AT silviacabrera patientderivedxenograftmodelsforendometrialcancerresearch AT angelgarcia patientderivedxenograftmodelsforendometrialcancerresearch AT tomvannyen patientderivedxenograftmodelsforendometrialcancerresearch AT danielaannibali patientderivedxenograftmodelsforendometrialcancerresearch AT tinafonnes patientderivedxenograftmodelsforendometrialcancerresearch AT augustvidal patientderivedxenograftmodelsforendometrialcancerresearch AT albertovillanueva patientderivedxenograftmodelsforendometrialcancerresearch AT xaviermatiasguiu patientderivedxenograftmodelsforendometrialcancerresearch AT camillakrakstad patientderivedxenograftmodelsforendometrialcancerresearch AT fredericamant patientderivedxenograftmodelsforendometrialcancerresearch AT antoniogilmoreno patientderivedxenograftmodelsforendometrialcancerresearch AT evacolas patientderivedxenograftmodelsforendometrialcancerresearch |